Sei Investments Co. Sells 8,840 Shares of Inspire Medical Systems, Inc. $INSP

Sei Investments Co. trimmed its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 17.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 42,100 shares of the company’s stock after selling 8,840 shares during the period. Sei Investments Co.’s holdings in Inspire Medical Systems were worth $2,171,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. CWM LLC lifted its stake in shares of Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after buying an additional 242 shares in the last quarter. Havemeyer Place LP bought a new stake in shares of Inspire Medical Systems during the fourth quarter valued at approximately $39,000. V Square Quantitative Management LLC purchased a new position in Inspire Medical Systems in the 4th quarter worth approximately $40,000. Smartleaf Asset Management LLC lifted its position in Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after acquiring an additional 205 shares in the last quarter. Finally, Larson Financial Group LLC lifted its position in Inspire Medical Systems by 21,266.7% in the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock valued at $48,000 after acquiring an additional 638 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors.

Inspire Medical Systems Trading Up 2.1%

Shares of INSP stock opened at $60.12 on Friday. Inspire Medical Systems, Inc. has a 12-month low of $38.91 and a 12-month high of $147.03. The stock has a market capitalization of $1.74 billion, a P/E ratio of 13.01, a P/E/G ratio of 4.57 and a beta of 0.70. The firm’s 50 day moving average is $47.64 and its 200 day moving average is $54.51.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s quarterly revenue was down 7.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities analysts predict that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Inspire Medical Systems in a report on Monday, August 3rd. Freedom Capital raised Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. UBS Group initiated coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They set a “sell” rating and a $39.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on Inspire Medical Systems from $54.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $60.00 target price on shares of Inspire Medical Systems in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Inspire Medical Systems has a consensus rating of “Hold” and an average target price of $68.00.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.